We likewise expected the pathways selected by MGSA for the mutation data would more effectively capture pathways known to be impacted by mutations that differ between lung adenocarcinoma and lung squamous cell carcinoma (e.g. pathways related to EGFR (39,41) and Interleukin signaling (42 44)). This evidence concerns the gene EGFR and lung adenocarcinoma.